Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)
- Autores: S. Keskin, I. Y?ld?z, F. Sen, F. Aydogan, L. Kilic, M. Ekenel, S. Saglam, B. Sakar, R. Disci, F. Aykan
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 15, Nº. 5, 2013, págs. 403-408
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose The aim of this retrospective study (from January 2007 to December 2011) was to investigate the efficacy and tolerability of mDCF schedule for chemotherapy-naïve AGC patients.
Patients Patients (n = 54) with locally inoperable or distant metastasis and performance status of 0�2 were eligible. The triplet combination chemotherapy consisting of docetaxel 60 mg/m2 on day 1, cisplatin 60 mg/m2 on day 1, and 5-fluorouracil 600 mg/m2 for 5 days of continuous infusion were administered every 21 days, up to nine cycles. Prophylactic G-CSF was not allowed.
Results In all, 36 (67 %) patients were male and 18 (33 %) were female; median age was 59 years. The majority of patients (n = 46, 85 %) had metastatic disease and 8 (15 %) of them had locally advanced disease. Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39 %) of the 46 cases, respectively. The median cycle of chemotherapy was 6. In assessing 50 patients for response evaluation, one had complete response. Partial response was achieved in 27 (54 %) patients. Seventeen patients (34 %) had stable disease and 5 (10 %) had progressive disease, while 4 % (n = 2) and 11 % (n = 6) of the patients developed severe (grade 3�4) neutropenia and anemia, respectively. During the median follow-up time (6.9 months, range 0.4�24), 28 (52 %) patients died. The overall and progression-free survival were 10.7 [95 % CI 8.9�12.4] and 6.8 [95 % CI 5.8�7.8] months, respectively.
Conclusions Although this was not a prospective comparative study, the mDCF regimen seems to be as effective as the original DCF in AGC with acceptable and manageable side effects.
